Endpoints News 生物医药· Ayisha Sharma·· 2026-10-06AI 评分50
AbbVie 与 Genmab 称 Epkinly 在一线 DLBCL 后期临床试验中取得成功
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
AI 导读
AbbVie 与 Genmab 表示,其 T 细胞衔接器 Epkinly 在一线弥漫性大 B 细胞淋巴瘤后期临床试验中取得成功,为潜在市场准入铺路。报道将该结果定位为对 Polivy 的挑战,原文未披露具体疗效数据。
正文
AbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news